Biotech Values

[DewDiligence]

At the end of IDIX’s Citi webcast, CFO Ron Renaud mentioned in passing that the phase-2b trials of IDX899 vs Sustiva (first-line setting) and IDX899 vs Intelence (second-line setting) are expected to start in late 2010 rather than the current quarte, as previously guided (#msg-47558107). Renaud also said the IDX899 + GSK1349572 phase-2b “nuke-sparing” trial is expected to start in early 2011 rather than late 2010, as previously guided.

Inasmuch as GSK is running these trials and is in charge of all information dissemination about IDX899, IDIX presumably can’t reveal the reason for the delays. Renaud may have slipped up by even mentioning the timeline on the webcast.